Home > posts > High Risk: The Debate Over the Price of Specialty Drugs and Zika Virus
September 27th, 2016 1:11 pm
High Risk: The Debate Over the Price of Specialty Drugs and Zika Virus
Posted by Print

In an interview with CFIF, Dr. Scott Gottlieb, Resident Fellow at the American Enterprise Institute, discusses the history and regulations surrounding drug prices, who should finance important medical advancements, and the continuing Zika threat.

Listen to the interview here.

Comments are closed.